Novobiocin-induced anti-proliferative and differentiating effects in melanoma B16

J. Nordenberg*, D. Albukrek, Tuvia Hadar, A. Fux, L. Wasserman, A. Novogrodsky, Y. Sidi

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


The antibiotic drug novobiocin was evaluated for its anti-tumour properties in B16 melanoma cells. Novobiocin is shown to inhibit melanoma B16 cell proliferation. The anti-proliferative effect was gradually reversible upon removal of novobiocin from the culture medium. Growth inhibition by novobiocin was accompanied by phenotypic alterations, that included morphological changes, lipid accumulation and marked increases in the activities of NADPH cytochrome c reductase and γ glutamyl transpeptidase. In vivo administration of repeated i.p. doses of novobiocin, to mice implanted with B16 melanoma cells resulted in growth retardation. The combined treatment of the B16 melanoma cells with novobiocin and other chemical inducers of differentiation was examined in a cell growth assay. Novobiocin and sodium butyrate inhibited cell growth in a near additive manner, while combination of novobiocin with the GTP-depleting agents, tiazofurin or mycophenolic acid resulted in a synergistic decrease in cell growth. Our results support the contention further that novobiocin and other differentiating agents might be of potential value in melanoma therapy.

Original languageEnglish
Pages (from-to)183-188
Number of pages6
JournalBritish Journal of Cancer
Issue number2
StatePublished - Feb 1992


FundersFunder number
Tel Aviv University


    Dive into the research topics of 'Novobiocin-induced anti-proliferative and differentiating effects in melanoma B16'. Together they form a unique fingerprint.

    Cite this